Question to the Department of Health and Social Care:

To ask His Majesty's Government what measures are being implemented to enable more people with early-stage dementia to participate in clinical trials for new treatments, and to ensure equitable access to trials across all regions.

Government responsibility for delivering dementia research is shared between the Department of Health and Social Care, with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.

The Department of Health and Social Care is committed to ensuring that all patients, including those with dementia, have access to cutting-edge clinical trials and innovative, lifesaving treatments.

As an example, the Department, via the NIHR, is investing nearly £50 million into the Dementia Trials Network, a coordinated network of trial sites across the United Kingdom, which will offer people with dementia the opportunity to take part in early phase clinical trials irrespective of where they live. This is complemented by the £20 million Dementia Trials Accelerator, designed to position the UK as the destination of choice for late phase clinical trials in dementia and neurodegenerative diseases.

The NIHR also funds research infrastructure which supports patients and the public to participate in high-quality research, including research on dementia. For example, the aim of the University College London Hospitals’ Biomedical Research Centre’s dementia theme is to develop novel treatments through precision medicine. The theme’s focus on young onset and familial dementias provides key insights into the factors that can cause or speed up neurodegeneration, allowing a window for treatments to be administered, before functional decline occurs.

In partnership with Alzheimer’s Society, Alzheimer’s Research UK, and Alzheimer Scotland, the NIHR also delivers Join Dementia Research, an online platform which enables the involvement of people with and without a dementia diagnosis, as well as carers, to take part in a range of important research, including studies evaluating potential treatments for dementia.

The Government’s Dame Barbara Windsor Dementia Goals programme, which is expected to have nearly £150 million of Government funding allocated to it, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation.